RS-504393 is a potent and highly selective CCR2 chemokine receptor antagonist with IC50s of 98 nM and > 100 µM for inhibition of human recombinant CCR2b and CCR1 receptors respectively.

Maraviroc (also known as UK-427857) is a potent, selective and non-competitive CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively.

MK0812 Succinate (MK-0812) is a novel, potent and selective small molecule CCR2 antagonist with anti-Inflammatory and immunomodulatory activity.

MK-0812 (MK0812) is a novel, potent and selective small molecule CCR2 antagonist with potential anti-Inflammatory and immunomodulatory activity.

ZK-756326 is a novel, selective, potent and non-peptide agonist of CCR8 chemokine receptor with an IC(50) value of 1.8 muM.

SB297006 (SB-297006) is an antagonist of CCR3 (Chemokine receptor, IC50 = 39 nM) with anticancer activity.

PF-4136309 (formerly known as INCB8761) is a novel, potent, selective, and orally bioavailable small molecule CCR2 antagonist with IC50 values of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2, respectively.

Aplaviroc (formerly known as AK-602; GW-873140; ONO-4128; GW873140A; GSK-873140), a SDP (spirodiketopiperazine) derivative, is a CCR5 entry inhibitor with the potential treatment of HIV infection.

GSK2239633A (GSK-2239633A), a 4-aminoindazole sulfonamide, is a novel and potent antagonist of human CC-chemokine receptor 4 (CCR4) with anti-inflammatory activity.

BX471 (also known as ZK-811752) is a novel, oral and non-peptide antagonist of CCR1 (CC chemokine receptor-1) with Ki of 1 nM for human CCR1, and it may be useful in the treatment of chronic inflammatory diseases.